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OBJECTIVES: With constant incentives for health care payers to contain their 
pharmaceutical budgets forecasting has become critically important. Some 
countries even developed pharmaceutical horizon scanning units. The objective of 
this project was to build a model to assess net effect of the entrance of new 
patented medicinal products versus medicinal products going off-patent, with a 
forecast horizon until 2016, on seven selected EU Member States’ pharmaceutical 
budgets: France, the UK, Germany, Poland, Portugal, Greece and Hungary. This 
model should take into account the ageing population, as well as current and future 
country-specific pricing, reimbursement and market access policies. (performed for 
the EU Commission -http://ec.europa.eu/health/healthcare 
/key_documents/index_en.htm) METHODS: A model was developed for generics 
and biosimilars for each country. This model estimated a separate and combined 
effect of the direct and indirect impact of patent cliff. A model was also developed 
for new entrants, which estimated the sales development and risk of development 
failure. New entrants were reviewed individually to assess their clinical potential 
and translate into commercial potential. Forecast was performed according to three 
perspectives (health care public payer, society and manufacturer), several types of 
distribution chain (retail, hospital, combined retail and hospital). Probabilistic and 
deterministic sensitivity analyses were carried out. RESULTS: All countries would 
experience drug budget reduction except Poland (€+41 million). Savings are 
expected to be the highest in the UK (€-9367 million), France (€-5589 million), and 
far behind, followed by Germany (€-831 million), Greece (€-808 million), Portugal (€-
243 million) and Hungary (€-84 million). Cardiovascular, central nervous system , 
respiratory areas and biosimilar entry will be the source of savings, while oncology, 
immunology and inflammation will lead for additional expenditure. The model is 
very sensitive to time to market branded products, generic prices, geneneric 
penetration, distribution of biosimilars. CONCLUSIONS: Pharmaceutical 
expenditures are expected to decrease in the analyzed period. The model is 
sensitive to policy decisions.  
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OBJECTIVES: Current mechanisms of pharmaceutical price control, as for instance 
international price referencing, may result in a convergence of pharmaceutical 
prices across countries at different levels of economic attainment. Within the EU, 
this process is intensified through the single European Market, which fosters 
parallel trade if price discrepancies for pharmaceuticals are sufficiently large. A 
narrow pharmaceutical price corridor within the EU should lead to 
disproportionally high percentages of pharmaceutical spending on total health 
care spending in lower income EU countries. This paper explores whether such a 
discrepancy exists between European countries after controlling for other factors 
potentially influencing the level of pharmaceutical spending. METHODS: We 
analysed OECD and EUROSTAT data from 21 European countries between 2001 
and 2010. A two-level hierarchical growth curve model was used to assess the 
relationship between pharmaceutical expenditure as percentage of total health 
expenditure and covariates both on measurement and country-level, including 
GDP, pharmaceutical and total health expenditure per capita, the cost of labour in 
EU member countries and life expectancy at birth. RESULTS: Initial results show 
an inverse relationship between GDP per capita and pharmaceutical expenditure 
as a percentage of total health expenditure. This relationship remains highly 
significant even after controlling for life expectancy at birth and differences in 
labour cost across EU member states. CONCLUSIONS: Pharmaceutical pricing 
policies within the EU put disproportionally high pressure on countries with more 
restricted health care budgets, which further limits access to health care - and 
thereby the potential to achieve health benefits - in lower income EU countries. 
Future analysis should use more disaggregated data and link pharmaceutical 
prices to health status and data on actual pharmaceutical consumption. 
Ultimately, new strategies of establishing differential pharmaceutical pricing 
across countries at different levels of economic attainment are needed to ensure 
universal and equitable access to innovative health care technologies.  
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OBJECTIVES: This study examines the dynamics of out-of-pocket health care 
spending by looking at the persistence of such spending among Medicare 
beneficiaries. It provides insight into how long high health care out-of-pocket 
spending persists, its association with certain health conditions and health 
shocks, and identify the determinants of the likelihood that an individual will be 
a persistent high health care spender. METHODS: This study uses the Health and 
Retirement Study (HRS) from 2001 to 2010. Descriptive statistics show 
concentration and persistence of out-of-pocket health care spending. Logistic 
model is used to study the likelihood of persistently being in the top percentiles 
of out-of-pocket health care spending among elderly adults who were initially in 
the top percentiles and to identify determinants of such probabilities. RESULTS: 
High out-of-pocket spending persisted for about six years and then remained 
fairly stable afterwards. Having a certain health condition such as diabetes, 
strokes or emotional problems increased the probability of persistence by up to 9 
percentage points. Compared to elderly adults who were covered by only 
Medicare, people having other government health insurance such as Medicaid, 
CHAMPUS, VA, or other military programs were about 19 percentage points less 
likely to be a persistently high out-of-pocket spender. By contrast, people who 
were covered by Medicare and any supplementary health insurance were more 
likely to be a persistently high spender. CONCLUSIONS: Non-trivial number of 
elderly adults remained in the same upper percentiles of the distribution for 
multiple years. The crucial factors that triggered high out-of-pocket spending on 
health care for several years were having certain chronic conditions or 
experiencing the onset of new health condition, even after controlling individual 
characteristics. Additionally, having an existing health insurance that 
supplements Medicare coverage or the acquisition of a new supplementary 
health insurance had a significant impact on the probability of persistence.  
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OBJECTIVES: Budget impact analysis (BIA) should be used alongside cost-
effectiveness analysis (CEA) to inform formulary decision-making. In the present 
analysis, US-published BIAs of pharmacological interventions were analyzed to 
assess trends in reported outcomes and conclusions. METHODS: Systematic 
searches (01/2002-12/2012) of PubMed and other sources (i.e., ISPOR/AMCP 
proceedings, manual reference search) were conducted to identify published 
BIAs reporting per-member per-month costs (PMPMC or equivalent) associated 
with the introduction of new pharmacotherapies. The outcome measures 
(PMPMC and BIA-author judgments of their own results) were analyzed 
descriptively. Associations between these two measures and other study 
characteristics (publication year and type, analytical horizon, and patient 
population size) were evaluated. RESULTS: Fifty BIAs were identified (40% via 
PubMed), reporting a total of 82 PMPMC outcome estimates (as some studies 
reported multiple populations/indications). Half were published in/after 2009. 
The median (min; max) PMPMC across all 82 estimates was 2 (-66; 894) cents 
(US$). Thirteen percent of all estimates were cost-saving while 75% and 95% 
were ≤5 and ≤90 cents, respectively. 65% of studies reported results between -5 
and +5 cents PMPM. No study characteristics were associated with PMPMC. In 
84% of studies the authors provided qualitative judgments of the acceptability of 
their BIA results. In 6% of studies and estimates, the PMPMC was reported as 
unacceptable. CONCLUSIONS: BIA results cluster within a narrow range (-5 to +5 
cents) and are nearly always reported as acceptable. These findings raise 
questions regarding the relevance and validity of published BIAs. In part, BIAs 
expressed in PMPMC (particularly in cents on the dollar) may easily provide a 
false impression of minimal impact. Whether BIA authors should self-judge the 
acceptability of PMPMC estimates is questionable. Without pre-defined 
benchmarks, judgments regarding BIA acceptability may be best left to decision-
makers and within the context of more comprehensive assessment (including 
notably CEA results).  
 
PHP68  
PHARMACEUTICAL EXPENDITURE FORECAST MODEL TO SUPPORT HEALTH 
POLICY DECISION MAKING  
Rémuzat C1, Toumi M2, Vataire AL3, Cetinsoy L3, Aballea S4 
1Creativ-Ceutical France, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France, 
3Creativ-Ceutical, PARIS, France, 4Creativ-Ceutical, Paris, France  
OBJECTIVES: With constant incentives for health care payers to contain their 
pharmaceutical budgets, modelling policy decision impact become critical. The 
objective of this project was to test various policy decisions on pharmaceutical 
budget (developed for the European Commission for the project “EU 
Pharmaceutical expenditure forecast” -http://ec.europa.eu/health/healthcare/ 
key_documents/index_en.htm). METHODS: We built a model to assess policy 
scenarios impact on pharmaceuticals reference forecast for seven EU Member 
States (France, the UK, Germany, Poland, Portugal, Greece and Hungary). The 
following scenarios were tested: expanding UK policies to EU, time to market 
access, reimbursement rate , generic price and penetration, distribution chain of 
biosimilars. RESULTS: Applying the UK policy would incur dramatic savings for 
Germany (10 times the reference forecast). France and Portugal would also enjoy 
substantial additional savings under this scenario (2 and 4 times the reference 
forecast respectively). Delaying time to market is very powerful to reduce the 
pharmaceuticals expenditure. While applying the EU transparency directive (6 
month-process for pricing and reimbursement), it would increase budget for all 
countries (from 1.1 to 4 times the reference forecast), except in Germany 
(additional savings). Decreasing price of generic and boosting the penetration 
rate, associated to distribution of biosimilar through hospital channel is a 
powerful way to reduce pharmaceuticals expenditure.In comparison, 
reimbursement rate has a modest impact. CONCLUSIONS: The most important 
leverages that were identified by the model on the pharmaceutical budget are 
driven by generic and biosimilar prices penetration rate and distribution. 
Reducing, even slightly, the prices of generics will have a major impact while 
reimbursement rate has less impact. Time to access for innovative products is an 
effective leverage used by some countries for delaying the bill.  
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BACKGROUND: The Mexican institute for social security IMSS represents alone 
44% of the total health care market in the country. Selling to this major client 
